This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
| INTRODUC TI ON
The presence of anti-HLA antibodies that are specific for ≥1 HLA alleles of the organ donor before transplant has been associated with very poor outcomes and, in many cases, graft loss through hyperacute and antibody-mediated rejection (ABMR). 1 In the past, the detection of donor-specific antibodies (DSAs) pretransplant was considered a contraindication to transplant. However, because the number of highly sensitized patients on the transplant waiting lists has increased, desensitizing strategies have been developed to allow such patients to benefit from transplant with a kidney from a living HLA-incompatible donor. [2] [3] [4] These strategies use preconditioning with cycles of high-dose intravenous Ig (IVIg), or plasmapheresis combined with low-dose IVIg, 5 but can include other agents such as rituximab. 6, 7 Desensitization has increased transplant rates, reduced waiting times, and provided a significant survival benefit for patients with DSA compared with waiting for an HLA-compatible transplant. 8 Transplant of an HLA-incompatible kidney after desensitization is, however, associated with an increased risk of ABMR, in both the short and longer term. 4, 9 To date, there is no standard protocol for desensitization that is effective in every patient with an anti-HLA antibody. 10 Each patient requires careful monitoring using complement-dependent cytotoxicity (CDC), flow cytometry crossmatch (FCXM), and/or multiplex single antigen bead (SAB) assays, before and after each round of treatment, to determine if the crossmatch has been rendered negative to enable transplant to proceed. The number of treatments required to reach a negative crossmatch depends on the characteristics of the anti-HLA antibodies present; a patient with low levels of DSA detected only by SAB analysis and FCXM may be desensitized after 2 to 4 cycles of treatment, whereas a patient with a positive CDC crossmatch usually requires many more cycles and additional agents to convert to a negative crossmatch, if it is ever attained. Each cycle of treatment is a burden for the patient and expensive. 11 The development of a more reliable, safe, and cost-effective approach for desensitization would offer a major benefit.
The IgG-degrading enzyme of Streptococcus pyogenes (IdeS [imlifidase]) is a 35-kDa cysteine protease identified in group A streptococci 12 where the enzyme inactivates opsonizing IgG antibodies bound to the bacterial surface. 13 IdeS specifically cleaves IgG molecules at the lower hinge region of the heavy chain in a multistep process. 12, [14] [15] [16] [17] Initially, IgG is degraded into single-cleaved IgG (scIgG), where 1 of the 2 IgG heavy chains is cut. This is followed by cleavage of the second heavy chain in the molecule, producing 1 F(ab') 2 and 1 homodimeric Fcfragment. offer an alternative to the currently used strategies for desensitization of patients with a positive crossmatch to an HLA-incompatible donor.
We report the findings from a phase 2 clinical study investigating the safety, immunogenicity, pharmacokinetics (PK), and efficacy of IV IdeS treatment in sensitized patients with CKD.
| MATERIAL S AND ME THODS

| Patients and study design
| Eligibility
Patients with CKD stage V, in dialysis, and on the waiting list for a kidney transplant at the Department of Surgical Sciences, Section of Transplant Surgery at Uppsala University Hospital, were eligible for the study if they had ≥2 identified HLA antibodies of which ≥1 was >3000 MFI in single antigen bead analysis on ≥2 separate occasions.
All eligible patients were prescreened and tested negative for the presence of IgE antibodies to IdeS.
| Approvals
The study protocol was approved by the regional ethics committee in Uppsala, Sweden (approval number 2014/131). All patients provided written informed consent.
| IdeS administration
IdeS was administered via IV infusion to patients enrolled in the study in ascending doses with an optional second dose within 48 hours. In group 1 (n = 3; patients 101, 102, and 103), patients (0.12 mg/kg ×2) and when the HLA-incompatible donor (HLA-B7 + ) kidney was offered, the HLA antibody profile was negative. The kidney was transplanted successfully. One patient (202) was given 0.25 mg/kg BW but the infusion was halted after about 4 minutes due to suspected infusion reactions.
The reaction resolved as soon as the infusion was interrupted, and the infusion was not restarted. 
| Crossmatching, anti-HLA antibody and total IgG analysis
At each time-point, CDC PRA analysis was performed as previously described. 19 The specificity and MFI of circulating HLA antibodies were determined by using SAB assays (One Lambda) on a Luminex platform. In selected cases, C1q binding assays were performed (One Lambda). The combined concentration of intact IgG and scIgG was investigated by using ELISA. 
| Pharmacokinetics and pharmacodynamics
Each subject underwent serial PK sampling for 3 weeks after IdeS infusion. Serum concentrations of IdeS were determined with a validated electrochemiluminescence immunoassay where IdeS was captured by a coated hen anti-IdeS antibody. Bound IdeS was detected by using a biotinylated rabbit anti-IdeS antibody followed by streptavidin-Sulfo (assay range 100 ng/mL-3000 ng/ mL). All serum samples were diluted in dissociation buffer before analysis to avoid interactions between IdeS and anti-IdeS antibodies.
PK evaluations were performed by using WinNonlin Professional 
| Transplant
Transplant was not part of the study design but was allowed if a kidney was offered during the study period and the CDC and FCXM were negative. One patient in group 1 met these criteria (see Results).
| Statistical analysis
CDC antibody reactivity was analyzed with use of the paired t-test.
Cleavage 
| RE SULTS
| Patient characteristics
The demographics and baseline characteristics of the 8 patients enrolled in the study are presented in Table 1 .
| Pharmacokinetics
Maximum plasma concentrations (C max ) of IdeS were observed at the end of the 15-minute infusion or shortly thereafter. In patients who received a second dose, the second C max value was higher than the first value (see Figure 1 ). The plasma concentration curves showed a fast distribution phase with a mean half-life of 5 hours and a slow elimination phase with a mean half-life of 70 hours (range 50-300 hours) and were well described by a 2-compartment model. 
| IdeS degrades plasma IgG rapidly and efficiently
The efficacy of IdeS treatment on IgG was investigated by using an MFI >20 000 (above the quantitative range of the assay, Figure 4C ). 
| IdeS degrades BCR expressed by circulating CD19 + B cells
The integrity of membrane-bound IgG-BCR on circulating CD19 
| Anti-IdeS antibodies
At enrollment, none of the screened patients had detectable levels 
| AEs associated with IdeS infusion
The total number of AEs reported during the study was 76, of which 27 were classified as related (related AE is defined as possibly or probably related); 18 grade 1, 4 grade 2, and 5 grade 3 ( Table 2) . One patient experienced a suspected infusion reaction and dosing was interrupted. All symptoms were grade 1 (flushing, hypertension, hot flashes, sinus tachycardia, dyspnea, scleral hemorrhage, visual impairment) and resolved 11 minutes after the infusion was stopped.
Two patients (102 and 201) had increased levels of aspartate aminotransferase (AST) and alanine aminotransferase (ALT) reported as AEs, both of which were classified as related. These patients received prophylaxis with amoxicillin/clavulanic acid and 1 of the patients (patient 102; see later) also received tacrolimus. Both drugs can cause elevated liver enzyme levels.
When amoxicillin/clavulanic acid was stopped and tacrolimus was adjusted, the liver enzyme levels decreased to normal levels. PK-INR was normal throughout the follow-up period.
Albumin ranged between 25 and 30 g/L. Due to this finding, the amoxicillin/clavulanic acid was replaced with phenoxymethylpenicillin in subsequent patients, and no additional cases of elevated liver enzymes were observed.
| Transplant of an HLA-incompatible kidney after IdeS treatment
Transplant was allowed within the study if a kidney was offered during the study period and the CDC and FCXM were negative. One patient in group 1 met these criteria. The patient (102), a 60-year-old man with CKD (HLA-A2, 3; -B8, 14; -DR4, 15; -DQ3, 6), had renal agenesis with progressive renal failure. The patient had received a first kidney transplant in 1997 with a functional graft until 2010.
That kidney was lost due to chronic allograft nephropathy and the patient returned to peritoneal dialysis. At enrollment, HLA antibodies were detected by CDC with 69% PRAs (Table 1) . A total of 13 circulating anti-HLA antibodies of known specificity with an MFI >500
were defined using SAB assays; HLA-A1, -A66, -B7, -B13, -B27, -B47, -B48, -B60, -B61, B73, -B81, -Cw4, and -Cw17. The data obtained in this phase 2 clinical study demonstrate that
IdeS treatment in sensitized patients with CKD is not only effective but also safe and well tolerated and has the potential to generate a window of 7 days after treatment when HLA antibodies are reduced below the threshold level, enabling the patient to be a candidate for transplant with an organ from an HLA-incompatible donor.
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Normal creatinine levels in patient 102 after transplant. Plasma creatinine levels at different time-points in an IdeS-treated recipient transplanted with an HLA-incompatible kidney from a deceased donor
